The endocannabinoid system as an emerging target of pharmacotherapy
The recent identification of cannabinoid receptors and their endogenous lipid ligands has
triggered an exponential growth of studies exploring the endocannabinoid system and its …
triggered an exponential growth of studies exploring the endocannabinoid system and its …
The emerging role of the endocannabinoid system in endocrine regulation and energy balance
During the last few years, the endocannabinoid system has emerged as a highly relevant
topic in the scientific community. Many different regulatory actions have been attributed to …
topic in the scientific community. Many different regulatory actions have been attributed to …
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized …
FX Pi-Sunyer, LJ Aronne, HM Heshmati, J Devin… - Jama, 2006 - jamanetwork.com
ContextRimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight
and improve cardiometabolic risk factors in patients who are overweight or obese …
and improve cardiometabolic risk factors in patients who are overweight or obese …
Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds
SM Grundy - Journal of the American College of Cardiology, 2006 - jacc.org
The metabolic syndrome is a constellation of risk factors of metabolic origin that are
accompanied by increased risk for cardiovascular disease and type 2 diabetes. These risk …
accompanied by increased risk for cardiovascular disease and type 2 diabetes. These risk …
Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia
Context: Cannabinoid CB1 receptor blockade decreases weight and hyperinsulinemia in
obese animals and humans in a way greatly independent from food intake. Objective: The …
obese animals and humans in a way greatly independent from food intake. Objective: The …
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity
M Bluher, S Engeli, N Kloting, J Berndt, M Fasshauer… - Diabetes, 2006 - Am Diabetes Assoc
The endocannabinoid system has been suspected to contribute to the association of visceral
fat accumulation with metabolic diseases. We determined whether circulating …
fat accumulation with metabolic diseases. We determined whether circulating …
Cannabinoid receptors as therapeutic targets
K Mackie - Annu. Rev. Pharmacol. Toxicol., 2006 - annualreviews.org
▪ Abstract CB1 and CB2 cannabinoid receptors are the primary targets of endogenous
cannabinoids (endocannabinoids). These G protein–coupled receptors play an important …
cannabinoids (endocannabinoids). These G protein–coupled receptors play an important …
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Background Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces
bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic …
bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic …
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
F Teixeira-Clerc, B Julien, P Grenard, JT Van Nhieu… - Nature medicine, 2006 - nature.com
Hepatic fibrosis, the common response associated with chronic liver diseases, ultimately
leads to cirrhosis, a major public health problem worldwide. We recently showed that …
leads to cirrhosis, a major public health problem worldwide. We recently showed that …
A biosynthetic pathway for anandamide
J Liu, L Wang, J Harvey-White… - Proceedings of the …, 2006 - National Acad Sciences
The endocannabinoid arachidonoyl ethanolamine (anandamide) is a lipid transmitter
synthesized and released “on demand” by neurons in the brain. Anandamide is also …
synthesized and released “on demand” by neurons in the brain. Anandamide is also …